Quantcast

Latest Targeted therapy Stories

2014-04-29 12:27:59

Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists' are optimistic that Boehringer Ingelheim's second-generation irreversible EGFR tyrosine kinase inhibitor (TKI) Gilotrif/Giotrif will offer efficacy and delivery advantages over currently available agents for the second- and...

2014-04-23 08:31:41

- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative...

2014-04-22 12:31:30

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/gastrointestinal_stromal_tumor_gist_global_clinical_trials_review.html Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Gastrointestinal Stromal Tumor (GIST) Global...

Researchers Discover Biomarker Leading To Cancer Drug Resistance
2014-04-21 07:52:12

redOrbit staff & Wire Reports – Your Universe Online Researchers from the University of California, San Diego School of Medicine have located a biomarker that they believe could help explain why many of the medications used to treat lung, breast and pancreatic cancers also promote drug resistance and ultimately cause tumors to form in patients. Writing in the April 20 online edition of Nature Cell Biology, the study authors report the discovery of a molecule known as CD61 that is...

2014-04-10 12:26:46

Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and...

2014-04-10 08:28:33

DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-04-08 12:31:44

Metronomic algorithms for targeted therapy to improve value of response and "failed drugs" for "resistant women's cancers" NEW YORK, April 8, 2014 /PRNewswire/ -- The following will be presented this week at the annual meeting of the American Association of Cancer Research, San Diego. Dr Howard Bruckner will present accumulating evidence describing a novel successful treatment for patients with resistant ovarian cancer. Low dose chemotherapy as cores, selected drug combinations,...

2014-04-03 12:30:00

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth SummaryGBI Research has released the pharma report "Monoclonal...

Gregory Tsongalis PhD
2014-03-26 03:00:14

Norris Cotton Cancer Center, Dartmouth College Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled "Personalized Therapy for Breast Cancer" was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods....

2014-03-25 12:29:41

Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014 /PRNewswire/ -- Decision Resources Group finds that efficacy more than any other factors drives oncologists' prescribing of targeted therapies for breast cancer and, according to the majority of surveyed oncologists, the escalating overall cost of drug treatment for breast cancer has little or no impact...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related